The Silicon Review
Headquartered in Mumbai, India, Lupin limited today produces a wide range of quality, affordable generic and branded formulations and APIs for the developed and developing markets of the world.The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds a global leadership position in the Anti-TB segment.
The Genesis of the Company
The company was named after the Lupin flower because of the inherent qualities of the flower and what it personifies and stands for. The Lupin flower is known to nourish the land, the very soil it grows in. The Lupin flower is also known to be tolerant of infertile soils and capable of pioneering change in barren and poor climes. The Lupin flower and bean pods have also long been used as food and sources of nourishment, thus protecting and nurturing life.
Embedded in Lupin was a formula for growth. Forty-six years on, what has stayed with the company is that same entrepreneurial spirit, the culture of creativity and innovation and pride in belonging to an industry that makes a difference in the lives of people. Lupin is today a fully integrated pharmaceutical company with an unrivaled position in the US, India,and Japan. This position is built on a backbone of cutting-edge research, world-class manufacturing facilities,and a truly global supply chain. With the building blocks in place, the future looks brighter than its ever been. Lupin is Built to Grow.
Lupin:Shaping a Better Future for Society
Dr. Desh Bandhu Gupta's vision and dream to fight life-threatening infectious diseases and to manufacture drugs of the highest social priority led to the formation of Lupin in the year 1968. His vision, his inimitable commitment,and verve have steered Lupin to achieving the distinction of becoming one of the fastest growing generic pharmaceutical companies globally. Lupin first gained recognition when it became one of the world's largest manufacturers of Tuberculosis drugs. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds a global leadership position in the Anti-TB segment.
The Company's R&D endeavors have resulted in significant progress in its NCE program. The Company's foray into Advanced Drug Delivery Systems has resulted in the development of platform technologies that are being used to develop value-added generic pharmaceuticals. Lupin's world-class manufacturing facilities, spread across India and Japan, have played a critical role in enabling the Company to realize its global aspirations. Benchmarked to international standards, these facilities are approved by international regulatory agencies like US FDA, UK MHRA, Japan's MHLW, TGA Australia, WHO, and the MCC South Africa. Our Drugs and products reach over 100 countries in the world.
Lupin is the 12th and 8th largest generics pharmaceutical company by market capitalization (March 31st, 2018, Bloomberg) and revenues (December 30th, 2017, Bloomberg LTM) respectively. The Company is the 4th largest pharmaceutical player in the US by prescriptions (IQVIA MAT March 2018); 3rd largest Indian pharmaceutical company by global revenues (December 30th, 2017, Bloomberg LTM); the 6th largest generic pharmaceutical player in Japan and 5th largest company in the Indian Pharmaceutical Market (IQVIA MAT March 2018). For the financial year ended 31st March 2018, Lupin’s Consolidated sales and Net profits were at Rs.155,598 million (USD 2.41 billion) and Rs. 2,513 million (USD 39 million) respectively.
The Values of Lupin
Integrity: We conduct ourselves with uncompromising integrity and honesty and insist on the highest ethical standards and transparency from our employees in all interactions. Everything we do must stand public scrutiny.
Passion for Excellence: We relentlessly pursue excellence through innovation and continuous improvement in all our projects, processes and products. To set our standards, we benchmark with the best in the World.
Teamwork: We align efforts and energies of our people across all levels and geographies to deliver outstanding results to our stakeholders. We encourage diverse opinions and yet work together in a coordinated and mutually supportive way.
Entrepreneurial Spirit: We empower our employees to generate new ideas, explore avenues and offer solutions that add exceptional value. We encourage them to build ownership in all endeavors by assuming responsibility with passion and conviction.
Respect and Care: We are compassionate and sensitive towards all our stakeholders and treat them the way we would expect to be treated. We provide an equal and fair opportunity for employment, learning and career development.
Customer Focus: We strive to understand and meet customer needs in a professional and responsive manner. We focus on building long-term partnerships for mutual benefit and take responsibility for delivering on our commitment.
The Leading Lady
Ms. Vinita Gupta, CEO:A graduate in pharmacy from the University of Mumbai and MBA from J L Kellog Graduate School of Management, Ms. Vinita Gupta has been instrumental in Lupin's forays into the Advanced Markets and heads the Advanced Market business of the company in the markets of the USA and Europe. Under her leadership, Lupin has emerged as a global generic player, especially in the US market in addition to becoming a strong player in the pediatric branded market. She is also a Chief Executive Officer Lupin Limitedon the Board of Lupin Ltd.
"Embedded in Lupin is a formula for growth which fuels creativity, performance,and innovation."
-Desh Bandhu Gupta, Founder, and Chairman of Lupin
The ongoing Covid pandemic had significantly increased the number of mobile and internet users worldwide. The high amount of usage is expected to drop...
Singapore’s open economy depends heavily on tourism and business. But its vibrant but small economy has been hurting as the circumstances due to...
2020 has been an unforgettable year for many of us. The ongoing Covid crisis has reminded people that it is very important to have an uninterrupted an...
Department of Telecommunications (DoT) is all set to announce the new schedule for 5G trials. The Dot made this decision after being pulled by the par...